Notably, FXR agonists, exemplified by OCA, have demonstrated efficacy in ameliorating liver fibrosis (with improvements of at least one grade) [130] and reducing steatosis levels by enhancing insulin sensitivity and modulating the bile acid–glucose–lipid metabolism axis [131,132]. The gene discussed is NR1H4; the disease is Hepatic fibrosis.